Company: ARWR
Filing Date: 2025-12-11
Form Type: S-3ASR
Source: 0001193125-25-314755
Chunk: 31

Company: ARROWHEAD PHARMACEUTICALS, INC.
Filing Date: 2025-12-11
Form: S-3ASR
Chunk 31
---
626) 304-3400. Additional information regarding our company, including our audited financial statements
and descriptions of our business, is contained in the documents incorporated by reference in this prospectus. See “Incorporation of Certain Information by Reference” and “Where You Can Find More Information” on page S-14 of this prospectus supplement.

S-4

THE OFFERING

| Shares of common stock offered by us | Shares of our common stock having an aggregate offering price of up to $500,000,000. |

| Shares of common stock to be outstanding after this offering | Up to 142,966,274 shares of common stock (as more fully described in the notes following this table), assuming sales of 7,264,274 shares of our common stock in this offering at an offering price of $68.83 per share, which was the last reported 
 sale price of our common stock on Nasdaq on December 9, 2025. The actual number of shares issued will vary depending on the sales prices under this offering.                                                                                       |

| Plan of Distribution | “At the market offering” that may be made from time to time through our sales agent, Jefferies. See the section entitled “Plan of Distribution” on page S-11 of this 
 prospectus supplement.                                                                                                                                               |

| Use of Proceeds | We intend to use the net proceeds from this offering for general corporate purposes, including working capital, capital expenditures, research and development expenditures, clinical trial expenditures, commercialization activity expenditures and  
 preparation for potential commercial launches of late stage products, including associated supply chain activities. A portion of the net proceeds may also be used for the acquisition of businesses, products and technologies or for other strategic 
 purposes. See the section titled “Use of Proceeds” on page S-8 of this prospectus supplement.                                                                                                                                                          |

| Risk Factors | See “Risk Factors” beginning on page S-6 of this prospectus supplement and in the documents incorporated by reference herein for a discussion of factors you should consider 
 carefully before investing in shares of our common stock.                                                                                                                    |

| Nasdaq symbol | “ARWR” |

The number of shares of our common stock to be outstanding after this offering is based on 135,702,000 shares of our common stock outstanding as of September 30, 2025, and excludes:

| • |     | 1,407,035 shares of our common stock subject to options outstanding as of September 30, 2025 under